Sort by
Refine Your Search
-
to development of hematological malignancies Department: Institute of Medical Genetics and Genomics Description: Hematological malignancies are closely related to various types of somatic mutations in blood cells
-
Department: Jan Křivánek Research Group: Dental Development and Regeneration – Faculty of Medicine Deadline: 31 Jan 2026 Start date: April 2026 or upon agreement Job type: full-time Job field
-
attitudes and representations evolved over the period examined by the project. The project is looking for researchers who will be able to develop independent research agendas in connection with the project
-
: The research group of prof. Michal Masařík is a biomedical laboratory dedicated to exploring the molecular mechanisms that drive cancer progression, with a particular emphasis on the tumour microenvironment (TME
-
opportunities or decisions based on race, colour, religion, sex, national origin, age, disability or sexual orientation. The faculty holds the HR Excellence Award. We are looking forward to hearing from you! Prof
-
on understanding the molecular mechanisms behind retinal development and disease using human pluripotent stem cells. We specialize in creating retinal organoids, “eye-like” organoids, and other retinal cell types
-
working hours Support for further education and professional development Benefits package: 6 weeks of paid vacation, medical insurance, financial contribution to meal and kindergarten/pension scheme
-
how it influences the spread of attitudes and behaviors within and between groups. The project combines theoretical development with empirical work, including longitudinal data collection and school
-
collaboration No teaching duties (teaching possible upon interest) Career development support (grant mentoring, publishing support, conference travel, potential internships) Flexible working hours The option of a
-
on immune cells and hematological malignancies. We aim to understand how changes in genome structure and regulation contribute to the development and progression of leukemia. Our new teammate will be